Dr. Jianping Huang is a leading expert in cancer immunotherapy and neuro-oncology research and clinical development, with over 20 years of experience translating immune-based treatments from bench to bedside. She founded Immunogenik and serves as Chief Scientific Officer, directing the company’s research and clinical strategy.

Dr. Huang is currently a Professor of Neurosurgery at the University of Florida and a former investigator at the National Cancer Institute (NCI), National Institutes of Health (NIH) where she conducted pioneering research in T cell therapy under the mentorship of Dr. Steven A. Rosenberg. Her work has contributed to the development of innovative CAR/TCR T cell and antibody-based therapies targeting solid tumors and hematological malignancies.

Dr. Huang has led multiple IND-enabling studies supported by STTR awards from the NCI/NIH. Her scientific leadership anchors Immunogenik’s mission to deliver transformative immunotherapies that are safer, more durable, and more effective for patients with limited treatment options. Together with the executive team, she is driving the company’s clinical pipeline forward and enabling global translation of its next-generation technologies.

Driven by a mission to overcome immune resistance in cancer, Dr. Huang combines deep immunological insight with clinical urgency to deliver transformative therapies for patients with limited treatment options.

‍